Mineralys Therapeutics Past Earnings Performance
Past criteria checks 0/6
Mineralys Therapeutics's earnings have been declining at an average annual rate of -61.1%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-61.1%
Earnings growth rate
0.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -64.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Oct 07
Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Sep 17We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03Revenue & Expenses Breakdown
How Mineralys Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -153 | 21 | 148 |
| 30 Jun 24 | 0 | -120 | 18 | 116 |
| 31 Mar 24 | 0 | -91 | 16 | 89 |
| 31 Dec 23 | 0 | -72 | 14 | 70 |
| 30 Sep 23 | 0 | -57 | 12 | 54 |
| 30 Jun 23 | 0 | -40 | 10 | 38 |
| 31 Mar 23 | 0 | -35 | 7 | 32 |
| 31 Dec 22 | 0 | -30 | 5 | 26 |
| 30 Sep 22 | 0 | -28 | 4 | 25 |
| 31 Dec 21 | 0 | -19 | 2 | 16 |
Quality Earnings: MLYS is currently unprofitable.
Growing Profit Margin: MLYS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MLYS is unprofitable, and losses have increased over the past 5 years at a rate of 61.1% per year.
Accelerating Growth: Unable to compare MLYS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MLYS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: MLYS has a negative Return on Equity (-64.68%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 22:18 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mineralys Therapeutics, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Charlie Yang | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |